The online submission platform for ERDERA’s Joint Transnational Call 2025 is now live

We are pleased to announce that the platform for submitting project applications for the Joint Transnational Call for Proposals (JTC) 2025 is now officially live. This highly anticipated call invites research teams across Europe and internationally to collaborate on cutting-edge projects aimed at “Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation.” 

How to Use the Platform 

The platform will allow you to: 

  • Register and provide all required personal data for project participants. 
  • Enter your finalised project description.

Access to the platform can be found here.

We strongly recommend registering early to familiarise yourself with the platform’s functionality. A template outlining the required data is available on the ERDERA Funding webpage to assist in your preparation. 

Application Timeline  

The JTC 2025 will follow a two-stage submission process:  

  • 13 February 2025: Pre-proposal submission deadline.  
  • 9 July 2025: Full proposals submission deadline.  

Funding decisions are expected by December 2025. 

For further details, access the updated call documents here. 

News & Updates

You might also be interested in

The European Conference on Rare Diseases & Orphan Products (ECRD) is the largest patient-led policy-shaping event on rare diseases in Europe.
Gathering key stakeholders, including EU policymakers, industry leaders, patient advocacy groups, researchers, and healthcare providers. Its goal is to identify concrete actions and incentives to enhance innovation across the rare disease ecosystem.
On November 12 at 11:00am (GMT+3) , IBG RareBoost will host Dr. Başak Uysal from the ERDERA Coordination Team. She will deliver a presentation titled “Accelerating Innovation Through Coordinated Research Platforms: The ERDERA Approach.”
Amsterdam and online, convening clinicians, scientists and advocates to share progress and the power of patient led policy to improve diagnosis and care.